Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the completion of enrollment in its Phase 2 B-SUPREME study evaluating pevifoscorvir sodium for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE